November 2012 Volume 8, Issue 11
Volume 8, Issue 11 | November 2012
November 2012
In this Issue
Tools & Technology
Life Technologies acquires Compendia Bioscience
Bioinformatics expertise completes foundation of Life Technologies’ oncology strategyA new view for Bruker
Bruker to acquire Carestream’s preclinical in-vivo imaging businessREFS for a different kind of judgment call
GNS Healthcare, Covance to create computer models to predict drug development successKeeping methyltransferases simple
BellBrook Labs and Reaction Biology collaborate on screening of methyltransferases for epigenetic drug discoveryGlobal News
Takeda goes viral
Takeda buys LigoCyte Pharmaceuticals for $60 million cash, adds norovirus vaccine to global pipelineGenerating growth with Genfar
Acquisition of Colombia-based company expands Sanofi’s Latin American presence, boosts animal health portfolioMaking renal disease a top priority
AstraZeneca to pay as much as $272.5 million plus royalties for license to Ardelyx’s NHE3 inhibitor programNanobodies for voltage-gated ion channels
Ablynx and Merck to develop therapeutic nanobody candidates in potential half-billion-dollar dealA match made in MDS
Baxter, Onconova to partner on anti-cancer compound for MDS, pancreatic cancerDiagnostics
Narrowing in on NuroPro
Amarantus, RBCC to focus on Parkinson’s diagnostic in joint ventureTwo new partners for Life
Life Technologies to partner with Bristol-Myers Squibb and CollabRx for companion diagnostics developmentPROOF, MRM Proteomics turn the peptides
Protein signatures could become companion diagnostics to optimize drug discovery and patient care managementA diagnostic boost to therapeutic success
ImaginAb and Lundbeck to collaborate in neurodegeneration deal revolving around central nervous system imaging with biologicsResearch & Development
All for one, one for all
Ten leading pharmas form nonprofit organization dedicated to alleviating clinical trial bottlenecksMatchmaking in the Midwest
BioSante and ANI Pharmaceutical merge in all-stock dealImmunological inhibitor
Astellas enters into license agreement with Janssen for RA therapyMJFF invests $5 million in Vandy-BMS Parkinson’s collaboration
Research targets the neurotransmitter glutamateA tremendous trio
CRI, Ludwig, MedImmune to test immunotherapy combinations for treatment of cancerLife-science companies launch rare disease research competition
Assay Depot and Rare Genomics Institute announced Oct. 15 that they have partnered with 19 life-science companies to launch the first Rare Disease Science ChallengeOmics & Systems Biology
Toward early dementia intervention
Janssen-funded public-private partnership compares Down Syndrome to Alzheimer’s diseaseInnovation, visibility and survival
Complete Genomics and BGI-Shenzhen announce merger agreementOf a giant and a gnome
Illumina acquires BlueGnome, a provider of cytogenetics and in-vitro fertilization screening solutionsPreparing to launch personalized medicine
Air Force longitudinal study aims to prepare healthcare providers for a world rife with personal genomic informationHR-TOFMS for the metabolome
LECO and Berkeley Lab partner on metabolomics researchGovernment Watch
Patent saga persists
ACLU and PUBPAT ask Supreme Court to disallow Myriad patents on breast cancer genesMeningitis outbreak plagues pharma industry
Regulators want more oversight of compounding pharmacies and regulation parity with drug manufacturersA third way for India
Supreme Court of India sets deadline for government to present national pharmaceutical pricing policyThe great debate, 21st century-style
Presidential Commission for Study of Bioethical Issues tackles privacy issues in whole-genome sequencingCommentary
Changing dynamics in the pharma and biotech industries
Reorganization, mergers and acquisitions (M&As), consolidation and portfolio changes are being evaluated to maintain growth centers in the face of a myriad of serious challenges. Overall, companies are looking to align with areas of growth opportunity as well as new business strategy and product development paradigms.I’m not sure about this, but …
Personalized medicine is intended to add several layers of information into the treatment decision to make it more likely that a patient will perform as desired during treatment or perhaps more accurately, that we’ll know how a patient will perform during treatment. But personalized medicine is an incredible uphill battle, as many companies and organizations have seen over the last decade.Editor's Focus
Pharma industry awaits impact of Obama’s second term
Now that the American people have spoken—with about 120 million votes estimated to have been cast as we went to press with this issue—and reelected President Barack Obama to a second term, many of you may be asking, “How will this affect pharma?”Special Reports
Signals in the noise (Part 1 of 2)
Informatics challenges hinder progress in personalized medicine developmentSignals in the noise (Part 2 of 2)
Informatics challenges hinder progress in personalized medicine developmentFeature
Discovery, ho!
American Society for Cell Biology forges path to more strongly connect basic sciences and drug discovery
Subscribe to our eNewsletters
Stay connected with all of the latest from Drug Discovery News.
SubscribeSponsored
Discovering deeper insights into malaria research
Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.
Accelerating RNA therapeutic testing with liver microphysiological platforms
Researchers can now study oligonucleotide delivery and efficacy in a system that models a real human liver.
Shining light on the subcellular proteome
Discover how innovative proteomics tools help researchers peer into once inaccessible organelles, allowing for new targets for drug discovery and development.
